MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
McKesson Corp (MCK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong financial performance, positive analyst sentiment, and favorable congressional trading activity. Despite a slight pre-market dip, the overall technical and fundamental indicators suggest a solid entry point.
The technical indicators for MCK are generally positive. The MACD histogram is above 0 and positively contracting, suggesting bullish momentum. The RSI is neutral at 54.105, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 897.168, R1: 956.286, S1: 838.05, R2: 992.81, S2: 801.526. The stock is trading near its resistance levels, indicating potential for upward movement.
Strong financial performance in Q3 2026 with revenue up 11.40% YoY, net income up 34.93% YoY, and EPS up 38.18% YoY.
Positive congressional trading activity with 4 purchase transactions and no sales in the last 90 days.
Analysts have raised price targets significantly, with JPMorgan setting a target of $1,107 and maintaining an Overweight rating.
Bullish moving averages and a positive MACD signal.
Slight pre-market price decline of -0.33%.
Neutral sentiment from hedge funds and insiders, with no significant trading trends observed recently.
McKesson reported strong Q3 2026 financials with revenue increasing to $106.16 billion (up 11.40% YoY), net income rising to $1.186 billion (up 34.93% YoY), EPS growing to $9.59 (up 38.18% YoY), and gross margin improving to 3.47% (up 1.76% YoY). These figures indicate robust growth and efficient operations.
Analyst sentiment is highly positive. JPMorgan raised the price target to $1,107, citing strong performance across core segments. Other firms like Baird, TD Cowen, and BofA have also raised their targets and maintained Buy or Overweight ratings. Analysts are optimistic about McKesson's execution and growth potential, particularly in its North American Pharmaceutical and Oncology & Multispecialty segments.
